Richard B. Warren
occupation: researcher
Articles 80
-
Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits
-
An evaluation of dermatology patients shielding during the COVID-19 outbreak
-
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
-
Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey
-
Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal
-
Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study
-
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review
-
Clinical and genetic differences between pustular psoriasis subtypes
-
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
-
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
-
Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials
-
One SNP at a Time: Moving beyond GWAS in Psoriasis
-
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis
-
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis
-
A novel mutation in IL36RN underpins childhood pustular dermatosis
-
Pharmacogenomics and the resulting impact on psoriasis therapies
-
Efficacy and safety of emerging immunotherapies in psoriasis.
-
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis.
-
The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures.
-
Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions.
-
Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies.
-
The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease.
-
The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease
-
Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients
-
Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools
-
Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis.
-
Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors.
-
Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.
-
Time for a 'joint' approach?
-
Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis
-
Expression of microRNA-184 in keratinocytes represses argonaute 2.
-
A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.
Human - wd:Q53755737